 Flutamide became the first NSAA to be tested clinically.Later the NSAAs bicalutamide and nilutamide were developed.The alleged advantages of these compounds were that they did not affect libido or potency like the other centrally acting compounds under development, luteinizing-hormone-releasing hormone (LHRH) agonists and cyproterone acetate.